{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:51:26Z","timestamp":1791553886294,"version":"4.3.4"},"reference-count":31,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070826"],"award-info":[{"award-number":["82070826"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,9,24]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1136\/jitc-2026-015661","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:15:16Z","timestamp":1791551716000},"page":"e015661","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic adenovirus-mediated delivery of anti-CLDN18.2 IgG3 for the treatment of solid tumors"],"prefix":"10.1136","volume":"14","author":[{"given":"Lei","family":"Pei","sequence":"first","affiliation":[{"name":"Advanced Institute for Medical Sciences, Dalian Medical University, Dalian, China"},{"name":"Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanrong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingguo","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Meng","sequence":"additional","affiliation":[{"name":"Institute of Health Sciences, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Institute of Health Sciences, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingrui","family":"Ma","sequence":"additional","affiliation":[{"name":"Institute of Health Sciences, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8518-5766","authenticated-orcid":false,"given":"Guangzuo","family":"Luo","sequence":"additional","affiliation":[{"name":"Advanced Institute for Medical Sciences, Dalian Medical University, Dalian, China"},{"name":"Institute of Health Sciences, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"2026100906150974000_14.10.e015661.1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1371421","article-title":"Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer","volume":"14","author":"Xu","year":"2024","journal-title":"Front Oncol"},{"key":"2026100906150974000_14.10.e015661.2","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao","year":"2022","journal-title":"Biomark Res"},{"key":"2026100906150974000_14.10.e015661.3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02056-x"},{"key":"2026100906150974000_14.10.e015661.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-10533-x","article-title":"Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cancer"},{"key":"2026100906150974000_14.10.e015661.5","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28400"},{"key":"2026100906150974000_14.10.e015661.6","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s10620-024-08435-4","article-title":"Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer","volume":"69","author":"Jin","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026100906150974000_14.10.e015661.7","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-026-01803-9","article-title":"Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies","volume":"19","author":"Xie","year":"2026","journal-title":"J Hematol Oncol"},{"key":"2026100906150974000_14.10.e015661.8","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1523096","article-title":"Characterization of zolbetuximab in pancreatic cancer models","volume":"8","author":"T\u00fcreci","year":"2019","journal-title":"Oncoimmunology"},{"key":"2026100906150974000_14.10.e015661.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0204"},{"key":"2026100906150974000_14.10.e015661.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00874-2"},{"key":"2026100906150974000_14.10.e015661.11","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026100906150974000_14.10.e015661.12","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1323159"},{"key":"2026100906150974000_14.10.e015661.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-179754"},{"key":"2026100906150974000_14.10.e015661.14","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2016.178","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"15","author":"Kaufman","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"2026100906150974000_14.10.e015661.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w"},{"key":"2026100906150974000_14.10.e015661.16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/cgt.2014.31","article-title":"Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land","volume":"21","author":"Guo","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"2026100906150974000_14.10.e015661.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0019-2"},{"key":"2026100906150974000_14.10.e015661.18","doi-asserted-by":"crossref","DOI":"10.3390\/v15081645","article-title":"Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective","volume":"15","author":"Muthukutty","year":"2023","journal-title":"Viruses"},{"key":"2026100906150974000_14.10.e015661.19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.20517\/jtgg.2024.74","article-title":"Review on gene and cell therapies in prostate cancer treatment: prospects and challenges","volume":"9","author":"Ibor","year":"2025","journal-title":"J Transl Genet Genom"},{"key":"2026100906150974000_14.10.e015661.20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"2026100906150974000_14.10.e015661.21","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026100906150974000_14.10.e015661.22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009901","article-title":"Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response","volume":"12","author":"Zhu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026100906150974000_14.10.e015661.23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26003-6","article-title":"An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma","volume":"12","author":"Xu","year":"2021","journal-title":"Nat Commun"},{"key":"2026100906150974000_14.10.e015661.24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/COH.0000000000000960","article-title":"Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches","volume":"20","author":"Naranjo-Gomez","year":"2025","journal-title":"Curr Opin HIV AIDS"},{"key":"2026100906150974000_14.10.e015661.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2017.12.006"},{"key":"2026100906150974000_14.10.e015661.26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200356"},{"key":"2026100906150974000_14.10.e015661.27","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149766"},{"key":"2026100906150974000_14.10.e015661.28","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813"},{"key":"2026100906150974000_14.10.e015661.29","doi-asserted-by":"publisher","DOI":"10.1126\/science.1118948"},{"key":"2026100906150974000_14.10.e015661.30","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70387","article-title":"Natural Killer Cell-Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications","volume":"6","author":"Luo","year":"2025","journal-title":"MedComm (2020)"},{"key":"2026100906150974000_14.10.e015661.31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1548292","article-title":"ADCC: the rock band led by therapeutic antibodies, tumor and immune cells","volume":"16","author":"Vincken","year":"2025","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:15:19Z","timestamp":1791551719000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,9]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/jitc-2026-015661"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015661","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}